Single-agent paclitaxel an option in operable breast cancer

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	1999

Schlagwörter:	Paclitaxel Doxorubicin Fluorouracil Objective Response Rate Disease Free Survival Rate

Anmerkung:	© Adis International Ltd 1999

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1218(1999), 1 vom: Dez., Seite 15-15
Übergeordnetes Werk:	volume:1218 ; year:1999 ; number:1 ; month:12 ; pages:15-15

Links:	Volltext

DOI / URN:	10.2165/00128413-199912180-00029

Katalog-ID:	SPR036295329

Internformat


LEADER	01000caa a22002652 4500
001	SPR036295329
003	DE-627
005	20230519095256.0
007	cr uuu---uuuuu
008	201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-199912180-00029 \|2 doi
035			\|a (DE-627)SPR036295329
035			\|a (SPR)00128413-199912180-00029-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Single-agent paclitaxel an option in operable breast cancer
264		1	\|c 1999
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 1999
650		4	\|a Paclitaxel \|7 (dpeaa)DE-He213
650		4	\|a Doxorubicin \|7 (dpeaa)DE-He213
650		4	\|a Fluorouracil \|7 (dpeaa)DE-He213
650		4	\|a Objective Response Rate \|7 (dpeaa)DE-He213
650		4	\|a Disease Free Survival Rate \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1218(1999), 1 vom: Dez., Seite 15-15 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1218 \|g year:1999 \|g number:1 \|g month:12 \|g pages:15-15
856	4	0	\|u https://dx.doi.org/10.2165/00128413-199912180-00029 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
951			\|a AR
952			\|d 1218 \|j 1999 \|e 1 \|c 12 \|h 15-15

Indexfelder

matchkey_str	article:22306056:1999----::igegnpciaeaotoioea
hierarchy_sort_str	1999
publishDate	1999
allfields	10.2165/00128413-199912180-00029 doi (DE-627)SPR036295329 (SPR)00128413-199912180-00029-e DE-627 ger DE-627 rakwb eng Single-agent paclitaxel an option in operable breast cancer 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Paclitaxel (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Disease Free Survival Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1218(1999), 1 vom: Dez., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1218 year:1999 number:1 month:12 pages:15-15 https://dx.doi.org/10.2165/00128413-199912180-00029 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1218 1999 1 12 15-15
spelling	10.2165/00128413-199912180-00029 doi (DE-627)SPR036295329 (SPR)00128413-199912180-00029-e DE-627 ger DE-627 rakwb eng Single-agent paclitaxel an option in operable breast cancer 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Paclitaxel (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Disease Free Survival Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1218(1999), 1 vom: Dez., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1218 year:1999 number:1 month:12 pages:15-15 https://dx.doi.org/10.2165/00128413-199912180-00029 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1218 1999 1 12 15-15
allfields_unstemmed	10.2165/00128413-199912180-00029 doi (DE-627)SPR036295329 (SPR)00128413-199912180-00029-e DE-627 ger DE-627 rakwb eng Single-agent paclitaxel an option in operable breast cancer 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Paclitaxel (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Disease Free Survival Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1218(1999), 1 vom: Dez., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1218 year:1999 number:1 month:12 pages:15-15 https://dx.doi.org/10.2165/00128413-199912180-00029 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1218 1999 1 12 15-15
allfieldsGer	10.2165/00128413-199912180-00029 doi (DE-627)SPR036295329 (SPR)00128413-199912180-00029-e DE-627 ger DE-627 rakwb eng Single-agent paclitaxel an option in operable breast cancer 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Paclitaxel (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Disease Free Survival Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1218(1999), 1 vom: Dez., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1218 year:1999 number:1 month:12 pages:15-15 https://dx.doi.org/10.2165/00128413-199912180-00029 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1218 1999 1 12 15-15
allfieldsSound	10.2165/00128413-199912180-00029 doi (DE-627)SPR036295329 (SPR)00128413-199912180-00029-e DE-627 ger DE-627 rakwb eng Single-agent paclitaxel an option in operable breast cancer 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1999 Paclitaxel (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Disease Free Survival Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1218(1999), 1 vom: Dez., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1218 year:1999 number:1 month:12 pages:15-15 https://dx.doi.org/10.2165/00128413-199912180-00029 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1218 1999 1 12 15-15
language	English
source	Enthalten in Inpharma weekly 1218(1999), 1 vom: Dez., Seite 15-15 volume:1218 year:1999 number:1 month:12 pages:15-15
sourceStr	Enthalten in Inpharma weekly 1218(1999), 1 vom: Dez., Seite 15-15 volume:1218 year:1999 number:1 month:12 pages:15-15
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Paclitaxel Doxorubicin Fluorouracil Objective Response Rate Disease Free Survival Rate
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	1999-12-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR036295329
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036295329</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519095256.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-199912180-00029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036295329</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-199912180-00029-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Single-agent paclitaxel an option in operable breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 1999</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Paclitaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Doxorubicin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluorouracil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Disease Free Survival Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1218(1999), 1 vom: Dez., Seite 15-15</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1218</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:1</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:15-15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-199912180-00029</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1218</subfield><subfield code="j">1999</subfield><subfield code="e">1</subfield><subfield code="c">12</subfield><subfield code="h">15-15</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	Single-agent paclitaxel an option in operable breast cancer Paclitaxel (dpeaa)DE-He213 Doxorubicin (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Disease Free Survival Rate (dpeaa)DE-He213
topic	misc Paclitaxel misc Doxorubicin misc Fluorouracil misc Objective Response Rate misc Disease Free Survival Rate
spellingShingle	misc Paclitaxel misc Doxorubicin misc Fluorouracil misc Objective Response Rate misc Disease Free Survival Rate Single-agent paclitaxel an option in operable breast cancer
topic_unstemmed	misc Paclitaxel misc Doxorubicin misc Fluorouracil misc Objective Response Rate misc Disease Free Survival Rate
topic_browse	misc Paclitaxel misc Doxorubicin misc Fluorouracil misc Objective Response Rate misc Disease Free Survival Rate
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	Single-agent paclitaxel an option in operable breast cancer
ctrlnum	(DE-627)SPR036295329 (SPR)00128413-199912180-00029-e
title_full	Single-agent paclitaxel an option in operable breast cancer
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	1999
contenttype_str_mv	txt
container_start_page	15
container_volume	1218
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-199912180-00029
title_sort	single-agent paclitaxel an option in operable breast cancer
title_auth	Single-agent paclitaxel an option in operable breast cancer
abstract	© Adis International Ltd 1999
abstractGer	© Adis International Ltd 1999
abstract_unstemmed	© Adis International Ltd 1999
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20
container_issue	1
title_short	Single-agent paclitaxel an option in operable breast cancer
url	https://dx.doi.org/10.2165/00128413-199912180-00029
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-199912180-00029
up_date	2024-07-03T16:57:40.064Z
_version_	1803577836242468864
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036295329</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519095256.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-199912180-00029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036295329</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-199912180-00029-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Single-agent paclitaxel an option in operable breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 1999</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Paclitaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Doxorubicin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluorouracil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Disease Free Survival Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1218(1999), 1 vom: Dez., Seite 15-15</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1218</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:1</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:15-15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-199912180-00029</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1218</subfield><subfield code="j">1999</subfield><subfield code="e">1</subfield><subfield code="c">12</subfield><subfield code="h">15-15</subfield></datafield></record></collection>
score	7.399705

Nicht das Richtige dabei?

Schreiben Sie uns!

Single-agent paclitaxel an option in operable breast cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?